Zevra Therapeutics, Inc. (ZVRA) 10-Year Financial Performance & Capital Metrics

ZVRA • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutZevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.Show more

Revenue $24M -14.0%
EBITDA -$81M -65.9%
Net Income -$106M -129.1%
EPS (Diluted) -2.28 -75.4%
Gross Margin 68.59% -23.2%
EBITDA Margin -341.41% -92.9%
Operating Margin -368.47% -104.0%
Net Margin -446.85% -166.5%
ROE -207.84% -209.1%
ROIC -101.36% -24.0%
Debt/Equity 1.52 +114.9%
Interest Coverage -11.84 +64.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 13.0%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Shares diluted 30.5% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 10.5x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y12.96%

3Y-6.24%

TTM240.47%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM140.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM131.81%

ROCE

10Y Avg-87.56%

5Y Avg-54.81%

3Y Avg-52.51%

Latest-71.71%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	12.84M	13.29M	28.65M	10.16M	27.46M	23.61M
Revenue Growth %	-	-	-	-	-	0.03%	1.16%	-0.65%	1.7%	-0.14%
Cost of Goods Sold+	84K	175K	336K	324K	2.94M	1.3M	2.06M	222K	2.94M	7.42M
COGS % of Revenue	-	-	-	-	0.23%	0.1%	0.07%	0.02%	0.11%	0.31%
Gross Profit+	-84K	-175K	-336K	-324K	9.89M	11.98M	26.59M	9.94M	24.52M	16.2M
Gross Margin %	-	-	-	-	0.77%	0.9%	0.93%	0.98%	0.89%	0.69%
Gross Profit Growth %	-	-1.08%	-0.92%	0.04%	31.54%	0.21%	1.22%	-0.63%	1.47%	-0.34%
Operating Expenses+	22.81M	34.47M	33.37M	54.27M	30.23M	17.59M	18.86M	52.5M	74.12M	103.2M
OpEx % of Revenue	-	-	-	-	2.35%	1.32%	0.66%	5.17%	2.7%	4.37%
Selling, General & Admin	8.88M	14M	12.77M	12.51M	10.82M	7.92M	8.7M	15.04M	35.09M	54.87M
SG&A % of Revenue	-	-	-	-	0.84%	0.6%	0.3%	1.48%	1.28%	2.32%
Research & Development	13.93M	20.47M	20.59M	41.76M	19.41M	8.84M	10.16M	19.8M	39.81M	42.09M
R&D % of Revenue	-	-	-	-	1.51%	0.67%	0.35%	1.95%	1.45%	1.78%
Other Operating Expenses	0	0	0	0	0	828K	0	17.66M	-775K	6.24M
Operating Income+	-22.81M	-37.48M	-33.37M	-55.9M	-20.34M	-5.61M	7.73M	-42.56M	-49.6M	-87M
Operating Margin %	-	-	-	-	-1.58%	-0.42%	0.27%	-4.19%	-1.81%	-3.68%
Operating Income Growth %	-0.39%	-0.64%	0.11%	-0.68%	0.64%	0.72%	2.38%	-6.51%	-0.17%	-0.75%
EBITDA+	-22.73M	-37.31M	-33.03M	-55.58M	-20.03M	-5.34M	7.99M	-41.62M	-48.6M	-80.61M
EBITDA Margin %	-	-	-	-	-1.56%	-0.4%	0.28%	-4.1%	-1.77%	-3.41%
EBITDA Growth %	-0.39%	-0.64%	0.11%	-0.68%	0.64%	0.73%	2.5%	-6.21%	-0.17%	-0.66%
D&A (Non-Cash Add-back)	84K	175K	336K	324K	304K	273K	257K	944K	1.01M	6.39M
EBIT	-22.81M	-34.47M	-33.37M	-54.27M	-18.03M	-5.7M	-8.14M	-26.47M	-44.55M	-82.79M
Net Interest Income+	-2.64M	-6.77M	-6.97M	-6.67M	-6.21M	-7M	-115K	1.18M	3.04M	-5.18M
Interest Income	32K	353K	365K	420K	309K	89K	261K	1.51M	4.54M	2.17M
Interest Expense	2.67M	7.13M	7.34M	7.09M	6.51M	7.09M	376K	335K	1.5M	7.35M
Other Income/Expense	-31.82M	20.95M	-10.06M	-689K	-4.21M	-7.18M	-16.25M	15.76M	3.56M	-3.14M
Pretax Income+	-54.64M	-16.53M	-43.43M	-56.59M	-24.54M	-12.79M	-8.52M	-26.8M	-46.05M	-90.14M
Pretax Margin %	-	-	-	-	-1.91%	-0.96%	-0.3%	-2.64%	-1.68%	-3.82%
Income Tax+	26K	-15K	-43K	-126K	-22K	-34K	34K	-33K	0	15.37M
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1.17%
Net Income+	-54.66M	-16.52M	-43.39M	-56.47M	-24.52M	-12.76M	-8.55M	-26.77M	-46.05M	-105.51M
Net Margin %	-	-	-	-	-1.91%	-0.96%	-0.3%	-2.63%	-1.68%	-4.47%
Net Income Growth %	-1.24%	0.7%	-1.63%	-0.3%	0.57%	0.48%	0.33%	-2.13%	-0.72%	-1.29%
Net Income (Continuing)	-54.66M	-16.52M	-43.39M	-56.47M	-24.52M	-12.76M	-8.55M	-26.77M	-46.05M	-105.51M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-118.69	-18.10	-47.37	-50.39	-13.23	-3.21	-2.11	-0.78	-1.30	-2.28
EPS Growth %	-2.73%	0.85%	-1.62%	-0.06%	0.74%	0.76%	0.34%	0.63%	-0.67%	-0.75%
EPS (Basic)	-118.69	-18.10	-47.37	-50.39	-13.23	-3.21	-2.11	-0.78	-1.30	-2.28
Diluted Shares Outstanding	460.54K	912.32K	915.81K	1.12M	1.85M	3.98M	29.77M	34.49M	35.45M	46.25M
Basic Shares Outstanding	460.54K	912.32K	915.81K	1.12M	1.85M	3.98M	29.77M	34.49M	35.45M	46.25M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	54.08M	74.36M	45.9M	23.72M	6.97M	8.38M	115.06M	92.83M	86.94M	86.03M
Cash & Short-Term Investments	51.32M	67.77M	42.23M	21.67M	3.22M	4.21M	112.35M	82.85M	67.74M	69.5M
Cash Only	32.32M	16.76M	10.87M	18.41M	3.22M	4.21M	112.35M	65.47M	43.05M	33.78M
Short-Term Investments	19M	51M	31.36M	3.26M	0	0	0	17.38M	24.69M	35.71M
Accounts Receivable	2.38M	5.06M	2.08M	140K	1.86M	2.58M	1.53M	8.3M	17.38M	10.51M
Days Sales Outstanding	-	-	-	-	53.02	70.84	19.47	298.11	230.97	162.45
Inventory	0	1.1M	0	0	0	0	0	0	24.08M	1.97M
Days Inventory Outstanding	-	2.29K	-	-	-	-	-	-	2.98K	96.95
Other Current Assets	0	58K	1.38M	0	1.37M	312K	252K	1.11M	-23.43M	3.02M
Total Non-Current Assets+	1.65M	10.53M	6.56M	3.02M	3.54M	2.83M	17.89M	22.51M	85.39M	92.1M
Property, Plant & Equipment	403K	1.97M	2M	1.75M	3.01M	2.39M	2.02M	1.78M	1.53M	1.01M
Fixed Asset Turnover	-	-	-	-	4.27x	5.56x	14.15x	5.70x	18.00x	23.31x
Goodwill	0	0	0	0	0	0	0	0	4.7M	4.7M
Intangible Assets	0	0	0	0	0	0	0	0	69.23M	68.99M
Long-Term Investments	0	8.2M	3.25M	0	0	0	15.42M	20M	0	6.01M
Other Non-Current Assets	1.24M	360K	1.31M	1.27M	527K	438K	438K	724K	9.94M	11.38M
Total Assets+	55.72M	84.89M	52.46M	26.75M	10.51M	11.21M	132.94M	115.34M	172.33M	178.13M
Asset Turnover	-	-	-	-	1.22x	1.19x	0.22x	0.09x	0.16x	0.13x
Asset Growth %	3.06%	0.52%	-0.38%	-0.49%	-0.61%	0.07%	10.86%	-0.13%	0.49%	0.03%
Total Current Liabilities+	8.34M	6.64M	11.51M	12M	5.43M	7.54M	4.23M	12.02M	73.72M	34.06M
Accounts Payable	1.25M	469K	2.18M	3.71M	1.14M	1.17M	516K	3.61M	13.99M	13.07M
Days Payables Outstanding	5.44K	978.2	2.36K	4.19K	141.29	328.36	91.47	5.94K	1.73K	643.44
Short-Term Debt	3.41M	0	3.33M	3.33M	0	390K	0	4.66M	37.7M	0
Deferred Revenue (Current)	0	0	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	0	41K	-5.59M	-4.51M	236K	0	821K	719K	10.82M	3.2M
Current Ratio	6.48x	11.19x	3.99x	1.98x	1.28x	1.11x	27.20x	7.72x	1.18x	2.53x
Quick Ratio	6.48x	11.03x	3.99x	1.98x	1.28x	1.11x	27.20x	7.72x	0.85x	2.47x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	1.48K	-384.04
Total Non-Current Liabilities+	57.5M	96.94M	98.46M	81.31M	79.53M	70.08M	1.59M	28.2M	36.74M	104.4M
Long-Term Debt	19.66M	91.17M	89.4M	78.11M	77.34M	68.05M	0	12.8M	5.07M	59.5M
Capital Lease Obligations	0	657K	562K	396K	1.9M	1.61M	1.24M	843K	456K	372K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	37.84M	5.11M	8.5M	2.81M	288K	427K	355K	14.55M	31.22M	44.52M
Total Liabilities	65.84M	103.58M	109.97M	93.31M	84.96M	77.62M	5.82M	40.22M	110.46M	138.46M
Total Debt+	23.1M	91.98M	93.48M	82.05M	79.53M	70.55M	1.61M	18.78M	43.77M	60.3M
Net Debt	-9.22M	75.22M	82.61M	63.64M	76.31M	66.33M	-110.74M	-46.69M	716K	26.51M
Debt / Equity	-	-	-	-	-	-	0.01x	0.25x	0.71x	1.52x
Debt / EBITDA	-	-	-	-	-	-	0.20x	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-13.87x	-	-	-
Interest Coverage	-8.54x	-5.26x	-4.55x	-7.89x	-3.12x	-0.79x	20.56x	-127.06x	-33.05x	-11.84x
Total Equity+	-10.12M	-18.7M	-57.52M	-66.57M	-74.46M	-66.41M	127.12M	75.12M	61.86M	39.67M
Equity Growth %	0.58%	-0.85%	-2.08%	-0.16%	-0.12%	0.11%	2.91%	-0.41%	-0.18%	-0.36%
Book Value per Share	-21.98	-20.49	-62.80	-59.40	-40.17	-16.68	4.27	2.18	1.74	0.86
Total Shareholders' Equity	-10.12M	-18.7M	-57.52M	-66.57M	-74.46M	-66.41M	127.12M	75.12M	61.86M	39.67M
Common Stock	1K	1K	1K	3K	0	0	4K	3K	4K	5K
Retained Earnings	-104.82M	-121.34M	-164.73M	-221.19M	-245.71M	-258.47M	-267.03M	-353.73M	-399.78M	-505.29M
Treasury Stock	0	0	0	0	0	0	-2.81M	-7.54M	-10.98M	-10.98M
Accumulated OCI	0	0	0	0	0	0	0	113K	-43K	631K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.27M	-29.77M	-33.1M	-54.2M	-23.74M	-1.94M	10.44M	-18.72M	-33.53M	-69.67M
Operating CF Margin %	-	-	-	-	-1.85%	-0.15%	0.36%	-1.84%	-1.22%	-2.95%
Operating CF Growth %	-0.38%	-0.47%	-0.11%	-0.64%	0.56%	0.92%	6.38%	-2.79%	-0.79%	-1.08%
Net Income	-54.66M	-16.52M	-43.39M	-56.47M	-24.52M	-12.76M	-8.55M	-41.54M	-46.05M	-105.51M
Depreciation & Amortization	84K	175K	336K	324K	304K	273K	257K	944K	1.01M	6.39M
Stock-Based Compensation	2.37M	6.6M	4.56M	6.5M	4.41M	2.49M	2.44M	4.29M	5.95M	14.91M
Deferred Taxes	1.91M	6.89M	164K	-5.98M	-2M	435K	16.2M	0	0	15.37M
Other Non-Cash Items	29.95M	-30.24M	6.87M	3.71M	3.19M	7.25M	460K	17.99M	-329K	5.82M
Working Capital Changes	87K	3.32M	-1.65M	-2.29M	-5.12M	374K	-357K	-406K	5.88M	-6.64M
Change in Receivables	0	0	0	0	-1.73M	-714K	1.05M	-6.77M	-9.08M	6.87M
Change in Inventory	0	0	0	0	5.51M	0	0	147K	206K	-8.87M
Change in Payables	0	1.12M	-801K	-1.64M	-3.79M	931K	-1.11M	3.13M	11.13M	-3.6M
Cash from Investing+	-19.14M	-46.95M	27.41M	33.33M	3.23M	-33K	-15.52M	-36.72M	-17.39M	-22.16M
Capital Expenditures	-135K	-643K	-181K	-21K	-26K	-33K	-102K	-93K	-296K	0
CapEx % of Revenue	-	-	-	-	0%	0%	0%	0.01%	0.01%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-19M	-1.1M	27.59M	33.35M	0	0	0	-36.63M	0	-6M
Cash from Financing+	61.47M	61.16M	-203K	28.02M	4.94M	2.74M	113.11M	8.35M	28.46M	82.11M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-2.44M	-1.01M	-46K	-116K	-300K	-34K	104.73M	291K	6.32M	1.3M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-20.4M	-30.41M	-33.28M	-54.22M	-23.76M	-1.97M	10.34M	-18.81M	-33.83M	-69.67M
FCF Margin %	-	-	-	-	-1.85%	-0.15%	0.36%	-1.85%	-1.23%	-2.95%
FCF Growth %	-0.39%	-0.49%	-0.09%	-0.63%	0.56%	0.92%	6.24%	-2.82%	-0.8%	-1.06%
FCF per Share	-44.30	-33.34	-36.34	-48.39	-12.82	-0.50	0.35	-0.55	-0.95	-1.51
FCF Conversion (FCF/Net Income)	0.37x	1.80x	0.76x	0.96x	0.97x	0.15x	-1.22x	0.70x	0.73x	0.66x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-	-	-28.18%	-26.48%	-67.23%	-207.84%
Return on Invested Capital (ROIC)	-	-151.19%	-61.32%	-378.27%	-822.25%	-473.47%	71.11%	-142.48%	-81.75%	-101.36%
Gross Margin	-	-	-	-	77.06%	90.18%	92.81%	97.82%	89.28%	68.59%
Net Margin	-	-	-	-	-191%	-96.03%	-29.86%	-263.48%	-167.69%	-446.85%
Debt / Equity	-	-	-	-	-	-	0.01x	0.25x	0.71x	1.52x
Interest Coverage	-8.54x	-5.26x	-4.55x	-7.89x	-3.12x	-0.79x	20.56x	-127.06x	-33.05x	-11.84x
FCF Conversion	0.37x	1.80x	0.76x	0.96x	0.97x	0.15x	-1.22x	0.70x	0.73x	0.66x
Revenue Growth	-	-	-	-	-	3.5%	115.61%	-64.53%	170.26%	-14.02%

Revenue by Segment

	2023
License	18M
License Growth	-

Frequently Asked Questions

Growth & Financials

Zevra Therapeutics, Inc. (ZVRA) reported $84.4M in revenue for fiscal year 2024.

Zevra Therapeutics, Inc. (ZVRA) saw revenue decline by 14.0% over the past year.

Yes, Zevra Therapeutics, Inc. (ZVRA) is profitable, generating $34.5M in net income for fiscal year 2024 (-446.9% net margin).

Dividend & Returns

Zevra Therapeutics, Inc. (ZVRA) has a return on equity (ROE) of -207.8%. Negative ROE indicates the company is unprofitable.

Zevra Therapeutics, Inc. (ZVRA) had negative free cash flow of $24.2M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Zevra Therapeutics, Inc. (ZVRA) 10-Year Financial Performance & Capital Metrics

ZVRA • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $24M -14.0%
EBITDA -$81M -65.9%
Net Income -$106M -129.1%
EPS (Diluted) -2.28 -75.4%
Gross Margin 68.59% -23.2%
EBITDA Margin -341.41% -92.9%
Operating Margin -368.47% -104.0%
Net Margin -446.85% -166.5%
ROE -207.84% -209.1%
ROIC -101.36% -24.0%
Debt/Equity 1.52 +114.9%
Interest Coverage -11.84 +64.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 13.0%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Shares diluted 30.5% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 10.5x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y12.96%

3Y-6.24%

TTM240.47%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM140.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM131.81%

ROCE

10Y Avg-87.56%

5Y Avg-54.81%

3Y Avg-52.51%

Latest-71.71%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	12.84M	13.29M	28.65M	10.16M	27.46M	23.61M
Revenue Growth %	-	-	-	-	-	0.03%	1.16%	-0.65%	1.7%	-0.14%
Cost of Goods Sold+	84K	175K	336K	324K	2.94M	1.3M	2.06M	222K	2.94M	7.42M
COGS % of Revenue	-	-	-	-	0.23%	0.1%	0.07%	0.02%	0.11%	0.31%
Gross Profit+	-84K	-175K	-336K	-324K	9.89M	11.98M	26.59M	9.94M	24.52M	16.2M
Gross Margin %	-	-	-	-	0.77%	0.9%	0.93%	0.98%	0.89%	0.69%
Gross Profit Growth %	-	-1.08%	-0.92%	0.04%	31.54%	0.21%	1.22%	-0.63%	1.47%	-0.34%
Operating Expenses+	22.81M	34.47M	33.37M	54.27M	30.23M	17.59M	18.86M	52.5M	74.12M	103.2M
OpEx % of Revenue	-	-	-	-	2.35%	1.32%	0.66%	5.17%	2.7%	4.37%
Selling, General & Admin	8.88M	14M	12.77M	12.51M	10.82M	7.92M	8.7M	15.04M	35.09M	54.87M
SG&A % of Revenue	-	-	-	-	0.84%	0.6%	0.3%	1.48%	1.28%	2.32%
Research & Development	13.93M	20.47M	20.59M	41.76M	19.41M	8.84M	10.16M	19.8M	39.81M	42.09M
R&D % of Revenue	-	-	-	-	1.51%	0.67%	0.35%	1.95%	1.45%	1.78%
Other Operating Expenses	0	0	0	0	0	828K	0	17.66M	-775K	6.24M
Operating Income+	-22.81M	-37.48M	-33.37M	-55.9M	-20.34M	-5.61M	7.73M	-42.56M	-49.6M	-87M
Operating Margin %	-	-	-	-	-1.58%	-0.42%	0.27%	-4.19%	-1.81%	-3.68%
Operating Income Growth %	-0.39%	-0.64%	0.11%	-0.68%	0.64%	0.72%	2.38%	-6.51%	-0.17%	-0.75%
EBITDA+	-22.73M	-37.31M	-33.03M	-55.58M	-20.03M	-5.34M	7.99M	-41.62M	-48.6M	-80.61M
EBITDA Margin %	-	-	-	-	-1.56%	-0.4%	0.28%	-4.1%	-1.77%	-3.41%
EBITDA Growth %	-0.39%	-0.64%	0.11%	-0.68%	0.64%	0.73%	2.5%	-6.21%	-0.17%	-0.66%
D&A (Non-Cash Add-back)	84K	175K	336K	324K	304K	273K	257K	944K	1.01M	6.39M
EBIT	-22.81M	-34.47M	-33.37M	-54.27M	-18.03M	-5.7M	-8.14M	-26.47M	-44.55M	-82.79M
Net Interest Income+	-2.64M	-6.77M	-6.97M	-6.67M	-6.21M	-7M	-115K	1.18M	3.04M	-5.18M
Interest Income	32K	353K	365K	420K	309K	89K	261K	1.51M	4.54M	2.17M
Interest Expense	2.67M	7.13M	7.34M	7.09M	6.51M	7.09M	376K	335K	1.5M	7.35M
Other Income/Expense	-31.82M	20.95M	-10.06M	-689K	-4.21M	-7.18M	-16.25M	15.76M	3.56M	-3.14M
Pretax Income+	-54.64M	-16.53M	-43.43M	-56.59M	-24.54M	-12.79M	-8.52M	-26.8M	-46.05M	-90.14M
Pretax Margin %	-	-	-	-	-1.91%	-0.96%	-0.3%	-2.64%	-1.68%	-3.82%
Income Tax+	26K	-15K	-43K	-126K	-22K	-34K	34K	-33K	0	15.37M
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1.17%
Net Income+	-54.66M	-16.52M	-43.39M	-56.47M	-24.52M	-12.76M	-8.55M	-26.77M	-46.05M	-105.51M
Net Margin %	-	-	-	-	-1.91%	-0.96%	-0.3%	-2.63%	-1.68%	-4.47%
Net Income Growth %	-1.24%	0.7%	-1.63%	-0.3%	0.57%	0.48%	0.33%	-2.13%	-0.72%	-1.29%
Net Income (Continuing)	-54.66M	-16.52M	-43.39M	-56.47M	-24.52M	-12.76M	-8.55M	-26.77M	-46.05M	-105.51M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-118.69	-18.10	-47.37	-50.39	-13.23	-3.21	-2.11	-0.78	-1.30	-2.28
EPS Growth %	-2.73%	0.85%	-1.62%	-0.06%	0.74%	0.76%	0.34%	0.63%	-0.67%	-0.75%
EPS (Basic)	-118.69	-18.10	-47.37	-50.39	-13.23	-3.21	-2.11	-0.78	-1.30	-2.28
Diluted Shares Outstanding	460.54K	912.32K	915.81K	1.12M	1.85M	3.98M	29.77M	34.49M	35.45M	46.25M
Basic Shares Outstanding	460.54K	912.32K	915.81K	1.12M	1.85M	3.98M	29.77M	34.49M	35.45M	46.25M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	54.08M	74.36M	45.9M	23.72M	6.97M	8.38M	115.06M	92.83M	86.94M	86.03M
Cash & Short-Term Investments	51.32M	67.77M	42.23M	21.67M	3.22M	4.21M	112.35M	82.85M	67.74M	69.5M
Cash Only	32.32M	16.76M	10.87M	18.41M	3.22M	4.21M	112.35M	65.47M	43.05M	33.78M
Short-Term Investments	19M	51M	31.36M	3.26M	0	0	0	17.38M	24.69M	35.71M
Accounts Receivable	2.38M	5.06M	2.08M	140K	1.86M	2.58M	1.53M	8.3M	17.38M	10.51M
Days Sales Outstanding	-	-	-	-	53.02	70.84	19.47	298.11	230.97	162.45
Inventory	0	1.1M	0	0	0	0	0	0	24.08M	1.97M
Days Inventory Outstanding	-	2.29K	-	-	-	-	-	-	2.98K	96.95
Other Current Assets	0	58K	1.38M	0	1.37M	312K	252K	1.11M	-23.43M	3.02M
Total Non-Current Assets+	1.65M	10.53M	6.56M	3.02M	3.54M	2.83M	17.89M	22.51M	85.39M	92.1M
Property, Plant & Equipment	403K	1.97M	2M	1.75M	3.01M	2.39M	2.02M	1.78M	1.53M	1.01M
Fixed Asset Turnover	-	-	-	-	4.27x	5.56x	14.15x	5.70x	18.00x	23.31x
Goodwill	0	0	0	0	0	0	0	0	4.7M	4.7M
Intangible Assets	0	0	0	0	0	0	0	0	69.23M	68.99M
Long-Term Investments	0	8.2M	3.25M	0	0	0	15.42M	20M	0	6.01M
Other Non-Current Assets	1.24M	360K	1.31M	1.27M	527K	438K	438K	724K	9.94M	11.38M
Total Assets+	55.72M	84.89M	52.46M	26.75M	10.51M	11.21M	132.94M	115.34M	172.33M	178.13M
Asset Turnover	-	-	-	-	1.22x	1.19x	0.22x	0.09x	0.16x	0.13x
Asset Growth %	3.06%	0.52%	-0.38%	-0.49%	-0.61%	0.07%	10.86%	-0.13%	0.49%	0.03%
Total Current Liabilities+	8.34M	6.64M	11.51M	12M	5.43M	7.54M	4.23M	12.02M	73.72M	34.06M
Accounts Payable	1.25M	469K	2.18M	3.71M	1.14M	1.17M	516K	3.61M	13.99M	13.07M
Days Payables Outstanding	5.44K	978.2	2.36K	4.19K	141.29	328.36	91.47	5.94K	1.73K	643.44
Short-Term Debt	3.41M	0	3.33M	3.33M	0	390K	0	4.66M	37.7M	0
Deferred Revenue (Current)	0	0	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	0	41K	-5.59M	-4.51M	236K	0	821K	719K	10.82M	3.2M
Current Ratio	6.48x	11.19x	3.99x	1.98x	1.28x	1.11x	27.20x	7.72x	1.18x	2.53x
Quick Ratio	6.48x	11.03x	3.99x	1.98x	1.28x	1.11x	27.20x	7.72x	0.85x	2.47x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	1.48K	-384.04
Total Non-Current Liabilities+	57.5M	96.94M	98.46M	81.31M	79.53M	70.08M	1.59M	28.2M	36.74M	104.4M
Long-Term Debt	19.66M	91.17M	89.4M	78.11M	77.34M	68.05M	0	12.8M	5.07M	59.5M
Capital Lease Obligations	0	657K	562K	396K	1.9M	1.61M	1.24M	843K	456K	372K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	37.84M	5.11M	8.5M	2.81M	288K	427K	355K	14.55M	31.22M	44.52M
Total Liabilities	65.84M	103.58M	109.97M	93.31M	84.96M	77.62M	5.82M	40.22M	110.46M	138.46M
Total Debt+	23.1M	91.98M	93.48M	82.05M	79.53M	70.55M	1.61M	18.78M	43.77M	60.3M
Net Debt	-9.22M	75.22M	82.61M	63.64M	76.31M	66.33M	-110.74M	-46.69M	716K	26.51M
Debt / Equity	-	-	-	-	-	-	0.01x	0.25x	0.71x	1.52x
Debt / EBITDA	-	-	-	-	-	-	0.20x	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-13.87x	-	-	-
Interest Coverage	-8.54x	-5.26x	-4.55x	-7.89x	-3.12x	-0.79x	20.56x	-127.06x	-33.05x	-11.84x
Total Equity+	-10.12M	-18.7M	-57.52M	-66.57M	-74.46M	-66.41M	127.12M	75.12M	61.86M	39.67M
Equity Growth %	0.58%	-0.85%	-2.08%	-0.16%	-0.12%	0.11%	2.91%	-0.41%	-0.18%	-0.36%
Book Value per Share	-21.98	-20.49	-62.80	-59.40	-40.17	-16.68	4.27	2.18	1.74	0.86
Total Shareholders' Equity	-10.12M	-18.7M	-57.52M	-66.57M	-74.46M	-66.41M	127.12M	75.12M	61.86M	39.67M
Common Stock	1K	1K	1K	3K	0	0	4K	3K	4K	5K
Retained Earnings	-104.82M	-121.34M	-164.73M	-221.19M	-245.71M	-258.47M	-267.03M	-353.73M	-399.78M	-505.29M
Treasury Stock	0	0	0	0	0	0	-2.81M	-7.54M	-10.98M	-10.98M
Accumulated OCI	0	0	0	0	0	0	0	113K	-43K	631K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.27M	-29.77M	-33.1M	-54.2M	-23.74M	-1.94M	10.44M	-18.72M	-33.53M	-69.67M
Operating CF Margin %	-	-	-	-	-1.85%	-0.15%	0.36%	-1.84%	-1.22%	-2.95%
Operating CF Growth %	-0.38%	-0.47%	-0.11%	-0.64%	0.56%	0.92%	6.38%	-2.79%	-0.79%	-1.08%
Net Income	-54.66M	-16.52M	-43.39M	-56.47M	-24.52M	-12.76M	-8.55M	-41.54M	-46.05M	-105.51M
Depreciation & Amortization	84K	175K	336K	324K	304K	273K	257K	944K	1.01M	6.39M
Stock-Based Compensation	2.37M	6.6M	4.56M	6.5M	4.41M	2.49M	2.44M	4.29M	5.95M	14.91M
Deferred Taxes	1.91M	6.89M	164K	-5.98M	-2M	435K	16.2M	0	0	15.37M
Other Non-Cash Items	29.95M	-30.24M	6.87M	3.71M	3.19M	7.25M	460K	17.99M	-329K	5.82M
Working Capital Changes	87K	3.32M	-1.65M	-2.29M	-5.12M	374K	-357K	-406K	5.88M	-6.64M
Change in Receivables	0	0	0	0	-1.73M	-714K	1.05M	-6.77M	-9.08M	6.87M
Change in Inventory	0	0	0	0	5.51M	0	0	147K	206K	-8.87M
Change in Payables	0	1.12M	-801K	-1.64M	-3.79M	931K	-1.11M	3.13M	11.13M	-3.6M
Cash from Investing+	-19.14M	-46.95M	27.41M	33.33M	3.23M	-33K	-15.52M	-36.72M	-17.39M	-22.16M
Capital Expenditures	-135K	-643K	-181K	-21K	-26K	-33K	-102K	-93K	-296K	0
CapEx % of Revenue	-	-	-	-	0%	0%	0%	0.01%	0.01%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-19M	-1.1M	27.59M	33.35M	0	0	0	-36.63M	0	-6M
Cash from Financing+	61.47M	61.16M	-203K	28.02M	4.94M	2.74M	113.11M	8.35M	28.46M	82.11M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-2.44M	-1.01M	-46K	-116K	-300K	-34K	104.73M	291K	6.32M	1.3M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-20.4M	-30.41M	-33.28M	-54.22M	-23.76M	-1.97M	10.34M	-18.81M	-33.83M	-69.67M
FCF Margin %	-	-	-	-	-1.85%	-0.15%	0.36%	-1.85%	-1.23%	-2.95%
FCF Growth %	-0.39%	-0.49%	-0.09%	-0.63%	0.56%	0.92%	6.24%	-2.82%	-0.8%	-1.06%
FCF per Share	-44.30	-33.34	-36.34	-48.39	-12.82	-0.50	0.35	-0.55	-0.95	-1.51
FCF Conversion (FCF/Net Income)	0.37x	1.80x	0.76x	0.96x	0.97x	0.15x	-1.22x	0.70x	0.73x	0.66x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-	-	-28.18%	-26.48%	-67.23%	-207.84%
Return on Invested Capital (ROIC)	-	-151.19%	-61.32%	-378.27%	-822.25%	-473.47%	71.11%	-142.48%	-81.75%	-101.36%
Gross Margin	-	-	-	-	77.06%	90.18%	92.81%	97.82%	89.28%	68.59%
Net Margin	-	-	-	-	-191%	-96.03%	-29.86%	-263.48%	-167.69%	-446.85%
Debt / Equity	-	-	-	-	-	-	0.01x	0.25x	0.71x	1.52x
Interest Coverage	-8.54x	-5.26x	-4.55x	-7.89x	-3.12x	-0.79x	20.56x	-127.06x	-33.05x	-11.84x
FCF Conversion	0.37x	1.80x	0.76x	0.96x	0.97x	0.15x	-1.22x	0.70x	0.73x	0.66x
Revenue Growth	-	-	-	-	-	3.5%	115.61%	-64.53%	170.26%	-14.02%

Revenue by Segment

	2023
License	18M
License Growth	-

Frequently Asked Questions

Growth & Financials

Zevra Therapeutics, Inc. (ZVRA) reported $84.4M in revenue for fiscal year 2024.

Zevra Therapeutics, Inc. (ZVRA) saw revenue decline by 14.0% over the past year.

Yes, Zevra Therapeutics, Inc. (ZVRA) is profitable, generating $34.5M in net income for fiscal year 2024 (-446.9% net margin).

Dividend & Returns

Zevra Therapeutics, Inc. (ZVRA) has a return on equity (ROE) of -207.8%. Negative ROE indicates the company is unprofitable.

Zevra Therapeutics, Inc. (ZVRA) had negative free cash flow of $24.2M in fiscal year 2024, likely due to heavy capital investments.